Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals insider buy: Director Saira Ramasastry purchases 2,000 shares, signaling cautious confidence amid volatile pricing and a 52‑week high decline.

Insider buying by Mirum Pharmaceuticals’ CFO signals confidence in cholestatic liver therapy pipeline—an optimistic outlook for investors.

Mirum Pharmaceuticals’ CMO’s 38% stake surge shows insider confidence, blending buy‑sell tactics with tax‑covering sales—insight for investors seeking growth prospects.

Mirum CEO’s latest share purchase signals confidence—while staggered sales manage tax and liquidity, investors watch insider activity for future growth cues.

Mirum Pharmaceuticals’ COO buys 5,912 shares, boosting confidence and signaling a bullish stance amid volatile earnings – investors should watch upcoming milestones.

CEO insider trading at Mirum Pharmaceuticals shows strategic buying, tax‑related selling, and long‑term stake—an insight for investors.

Insider buying by Mirum’s senior controller signals confidence amid volatility; discover how this move contrasts with CEO sales and what it means for investors.

Mirum’s top execs just grabbed massive stock options & RSUs— a bold sign of confidence amid rising share price and negative earnings. See what this insider surge could mean for investors.

Radovich Peter’s recent buy of 5,750 Mirum shares signals executive confidence amid a strong earnings beat, 104% yearly rally, and pipeline optimism, offering investors a bullish hint to watch.

Insider buy at Mirum Pharmaceuticals signals confidence amid a 104 % rally; 159k shares purchased by owner Heron Patrick J at $99.27, boosting optimism for liver‑disease pipeline.